VA-REGULA
3.4.2024 09:01:31 CEST | Business Wire | Press release
When it comes to verifying identity in remote scenarios, it’s generally through liveness checks that organizations try to ensure they are dealing with a real individual. Fraudsters are perfectly aware of this fact, and therefore seek to bypass verification using various tactics, predominantly presentation or injection attacks. The first type of fraud involves attempts to trick the system by presenting fake biometric traits, such as photos, videos, masks, etc. Injection attacks are done by inserting altered biometric data directly into the process of identity verification (IDV).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403567119/en/
A presentation attack scenario blocked by Regula Face SDK (Photo: Business Wire)
To help organizations secure remote IDV processes, Regula offers powerful technologies capable of detecting even the most sophisticated biometric fraud, including presentation and injection attacks. This latest update marks an advancement in Regula’s ability to detect certain types of spoofing attacks.
Enhanced security. Now, Regula Face SDK, a comprehensive solution for biometric verification, has reached a 99% rate in detecting and blocking presentation attacks done from electronic devices. Its anti-spoofing technology ensures that the face detected during the verification process is from an actively present and real person.
Streamlined user experience. Also, the new release of Regula Face SDK brings a new level of usability to biometric verification, thanks to the introduction of Passive Liveness technology. Utilizing neural networks trained on a diverse dataset, this technology verifies the genuine presence of an individual without any active participation from users (unlike Active Liveness) – the solution just requires them to take a selfie.
To obtain proper data for verification, i.e., a high-quality face image, Regula Face SDK uses an advanced image capture module that assesses image quality in real time, reducing the need for retakes. Followed by an instant liveness check, this approach significantly streamlines the overall verification process, making it faster and more user-friendly while maintaining high security standards.
“Remote onboarding is our new reality. More risky for organizations and definitely more preferable for users, it is about finding the perfect balance between security and convenience. The Passive Liveness feature is a delicate solution to this equation. It’s a very accessible single step for the user, improving user experience and elevating conversion rates. But that’s not all: Passive Authentication still ensures a high level of trustworthiness in the IDV process, as it effectively proves the presence and realness of an individual. Plus, for those who need ultimate security during onboarding or user verification, there is still the option of choosing Active Liveness, a more user-involving and robust technology for proving liveness,” says Ihar Kliashchou, Chief Technology Officer at Regula.
For the sake of greater convenience and faster interaction, the updated Regula Face SDK also supports face matching on mobile devices, without transmitting data to a server. Now, even if a smartphone is offline, it is still possible to compare a photo from a document with a selfie when identity verification is done not remotely, but on-site by an employee, for example in a bank when a client wants to open an account or get access to other financial services.
To learn more about the capabilities of the new version of Regula Face SDK, visit the official webpage.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403567119/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TACTICAAI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron22.10.2026 12:01:00 CEST | Press release
Collaboration brings together TACTICAAI’s operational decision-intelligence technology and NVIDIA AI capabilities to advance reasoning, autonomous analysis and video intelligence for real-world deployment TACTICAAI, an operational decision-intelligence company, today announced a collaboration with NVIDIA to advance and scale the deployment of agentic AI capabilities. The companies will work together to integrate and optimize NVIDIA Nemotron models within TACTICAAI’s multi-intelligence platform, with a focus on expanding these capabilities and supporting deployment with major customers internationally. The collaboration was announced at NVIDIA GTC Berlin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022054475/en/ TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron (Graphic: AETOSWire) The collaboration with NVIDIA builds on the company’s existing technology, integrating selected NVIDIA
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 522.10.2026 12:01:00 CEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has
Bregal Milestone Backs Nethive With Majority Growth Investment and JoyComm Acquisition22.10.2026 10:00:00 CEST | Press release
Partnership to support Nethive’s next phase of growth as a leading cybersecurity services and software platform Bregal Milestone, a leading European software growth private equity firm, today announced a majority growth investment in Nethive S.p.A. (“Nethive” or the “Company”), a leading Italian cybersecurity services and software provider. Alongside its investment in Nethive, Bregal Milestone has also backed Nethive’s acquisition of IT security specialist Joy Comm S.r.l. (“JoyComm”). Founded in 2014 by Alessandro Bellato and Diego Rocco, Nethive has become a trusted cybersecurity partner to blue-chip enterprises, SMEs, and public-sector organizations across Italy. Its platform spans managed security services, professional services and technology resale, helping organizations protect critical infrastructure and networks, strengthen cyber resilience and reduce operational complexity. Nethive combines deep technical expertise with 24/7 monitoring, threat detection and response, risk and
EOS and VOP CZ Sign Memorandum of Understanding to Explore Cooperation on Czech Programmes22.10.2026 09:00:00 CEST | Press release
EOS Defence Systems (EOS) and VOP CZ have signed a Memorandum of Understanding (MoU) at Future Forces Forum in Prague to explore cooperation on wheeled armoured vehicle programmes for the Czech Army and other future defence projects in the Czech Republic and Europe where VOP CZ is involved. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021408045/en/ EOS and VOP CZ sign a Memorandum of Understanding at Future Forces Forum in Prague. Left to right: Martin van de Voorde, Sales Director Europe, EOS; Vlastimil Navrátil, Managing Director, VOP CZ; Pavla Ungrová, Sales Director, VOP CZ; Rear Admiral Richard Caton, Australia’s Military Representative to NATO and the EU; Group Captain Michael Schleeman, Australia’s Defence Attaché; and Matej Pupák, Program Lead, VOP CZ. The agreement brings together EOS' expertise in advanced remote weapon systems (RWS) with VOP CZ's established capabilities in military vehicle integration, produ
Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease22.10.2026 09:00:00 CEST | Press release
Ferreri and Prilenia Therapeutics B.V.today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington's disease (HD) has received authorization to begin in participating EU Member States (EU CT number: 2026-526093-16-00, NCT07609108). Recruitment in the EU is expected to commence this month, joining currently recruiting sites in the US and UK, with Canada to follow. Designed to evaluate the efficacy and safety of pridopidine (administered as an oral capsule twice a day), and to generate data for regulatory evaluation, the global, approximately 400-participant, randomized, double-blind, placebo-controlled PRECISE-HD study will assess the clinical effect of the investigational treatment on disease progression, functional capacity, motor function, cognition, speech and quality of life. “The initiation of PRECISE-HD in Europe marks a milestone for the Huntington’s disease research community. This confirmatory Phase 3 study has been designed to bu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
